Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04418817 · ClinicalTrials.gov registry record
Modulus in XLIF Study
A clinical trial, sponsored by NuVasive.
- Completed
- Registry status
- 36
- Enrollment target
NCT04418817: Completed study, sponsored by NuVasive.
NCT04418817 is a clinical trial that has completed, run by NuVasive. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04418817 has completed, sponsored by NuVasive.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and performance of the Modulus 3D-printed titanium interbody implant in patients undergoing thoracic and/or lumbar XLIF as measured by reported complications, radiographic outcomes, and patient-reported outcomes.
Primary Outcome
Rate of complications attributable to use of the Modulus XLIF interbody implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-03-22 |
| Est. Completion | 2024-01-31 |
What the finished NCT04418817 record still lists
NCT04418817 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04418817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04418817 about?
NCT04418817 is a clinical study titled "Modulus in XLIF Study". The primary objective of this study is to evaluate the safety and performance of the Modulus 3D-printed titanium interbody implant in patients undergoing thoracic and/or lumbar XLIF as measured by reported complications, radiographic outcomes, and patient-reported outcomes.
What is the current status of trial NCT04418817?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2020-03-22. Estimated completion is 2024-01-31.
Who is sponsoring clinical trial NCT04418817?
This trial is sponsored by NuVasive, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI